Journal article
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
Abstract
ABSTRACT Aims The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomised, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorised according to left ventricular ejection fraction and tolerability to an ACE inhibitor. We conducted a pharmacogenomic study of the CHARM studies to identify genetic predictors of …
Authors
Dubé M-P; Chazara O; Lemaçon A; Asselin G; Provost S; Barhdadi A; Perreault L-PL; Mongrain I; Wang Q; Carss K
Journal
, , ,
Publisher
Cold Spring Harbor Laboratory
DOI
10.1101/2021.09.28.21263908